Mabel Ryder1,2, Mark Wentworth3, Alicia Algeciras-Schimnich4, John C Morris1,2, James Garrity5, Jane Sanders6, Stuart Young6, Paul Sanders6, Jadwiga Furmaniak6, Bernard Rees Smith6. 1. Division of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA. 2. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA. 3. Office of Research Regulatory Support, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA. 6. AV7 Limited, FIRS Laboratories, Cardiff, United Kingdom.
Abstract
Background: We report the therapeutic use of K1-70™, a thyrotropin receptor (TSHR) antagonist monoclonal antibody, in a patient with follicular thyroid cancer (FTC), Graves' disease (GD), and Graves' ophthalmopathy (GO). Methods: A 51-year-old female patient, who smoked, presented in October 2014 with FTC complicated by GD, high levels of TSHR autoantibodies with high thyroid stimulating antibody (TSAb) activity, and severe GO. K1-70 was administered at 3 weekly intervals with the dose adjusted to block TSAb activity. Her cancer was managed with lenvatinib and radioiodine therapy. Results: Following initiation of K1-70 therapy, TSAb activity measured in serum decreased and GO (proptosis and inflammation) improved. On K1-70 monotherapy during the pause in lenvatinib, several metastatic lesions stabilized while others showed progression attenuation compared with that before lenvatinib therapy. Conclusions: These observations suggest that blocking TSHR stimulation with K1-70 can be an effective treatment for GO and may also benefit select patients with FTC and GD.
Background: We report the therapeutic use of K1-70™, a thyrotropin receptor (TSHR) antagonist monoclonal antibody, in a patient with follicular thyroid cancer (FTC), Graves' disease (GD), and Graves' ophthalmopathy (GO). Methods: A 51-year-old female patient, who smoked, presented in October 2014 with FTC complicated by GD, high levels of TSHR autoantibodies with high thyroid stimulating antibody (TSAb) activity, and severe GO. K1-70 was administered at 3 weekly intervals with the dose adjusted to block TSAb activity. Her cancer was managed with lenvatinib and radioiodine therapy. Results: Following initiation of K1-70 therapy, TSAb activity measured in serum decreased and GO (proptosis and inflammation) improved. On K1-70 monotherapy during the pause in lenvatinib, several metastatic lesions stabilized while others showed progression attenuation compared with that before lenvatinib therapy. Conclusions: These observations suggest that blocking TSHR stimulation with K1-70 can be an effective treatment for GO and may also benefit select patients with FTC and GD.
Entities:
Keywords:
Graves' ophthalmopathy; TSH receptor; antibody drugs; autoantibodies; thyroid cancer
Authors: Jadwiga Furmaniak; Jane Sanders; Paul Sanders; Yang Li; Bernard Rees Smith Journal: Clin Endocrinol (Oxf) Date: 2022-02-06 Impact factor: 3.523